摘要
卵巢癌是致死率第一位的女性生殖系统恶性肿瘤,晚期卵巢癌的标准治疗为恶性肿瘤细胞减灭术联合化疗及靶向治疗。既往患者在化疗中及化疗后的不良反应主要采用临床医生报告结局(Clinician-Reported Outcome,ClinRO)进行评估。近年来,临床实践中一种新兴且可靠的患者健康状况评估方法——患者报告结局(Patient-Reported Outcome,PRO)日渐得到广泛关注。目前常用的PRO量表包括PRO-不良反应事件评价标准(Common Terminology Criteria for Adverse Events,CTCAE)、MDASI(M.D.Anderson Symptom Inventory)和QLQ-C30等,能够对患者健康状况进行多方面评估,监测临床症状,干预临床治疗和评估治疗方案,改善患者预后。但是,目前的PRO量表中部分项目的评估效果尚未得到有效验证,缺乏对于特定患者群体的队列研究。未来仍需进一步改进PRO量表和相关研究内容,以期获得更好的效果。
Ovarian cancer is the most lethal malignancy of the female reproductive system and the standard treatment of advanced ovarian cancer is cytoreductive surgery combined with chemotherapy and targeted therapy. Previously, patients′ adverse effects during and after chemotherapy were mainly assessed by Clinician-Reported Outcome (ClinRO). However, an emerging and reliable method of assessing patient health status Patient-Reported Outcome (PRO), has gained wide spread attention in clinical practice. Nowadays, commonly used PRO scales include PRO-Common Terminology Criteria for Adverse Events (CTCAE), M.D. Anderson Symptom Inventory (MDASI), QLQ-C30, etc., which can capable of multiple aspects of patient health status, detect clinical symptoms, intervene in clinical care and evaluate treatment options, and improve patient prognosis. However, the evaluation effect of some items in current PRO scales has not been effectively verified, and there is a lack of cohort studies for specific patient groups. Further improvement of the PRO scale and related studies is needed to achieve better results.
作者
王建璋
阮丹华
赵天浪
刘芮
张徐洋
曾靖(审校)
尹如铁
WANG Jian-zhang;RUAN Dan-hua;ZHAO Tian-lang;LIU Rui;ZHANG Xu-yang;ZENG Jing;YIN Ru-tie(West China School of Medicine,Sichuan University,Chengdu 610041,China;West China School of Basic Medical Sciences&Forensic Medcine,Sichuan University,Chengdu 610041,China;Department of Tumor Radiotherapy and Chemotherapy,Key Laboratory of Birth Defects and Related Diseases of Women and Children,Ministry of Education,West China Second University Hospital,Sichuan University,Chengdu 610041,China)
出处
《国际妇产科学杂志》
CAS
2023年第5期573-577,共5页
Journal of International Obstetrics and Gynecology
关键词
卵巢肿瘤
药物疗法
联合
患者报告结局评价
患者健康问卷
治疗
预后
Ovarian neoplasms
Drug therapy,combination
Patient reported outcome measures
Patient health questionnaire
Therapy
Prognosis
